Oruka Therapeutics (ORKA) Return on Capital Employed (2011 - 2024)
Oruka Therapeutics (ORKA) posted quarterly Return on Capital Employed of 26.85% for Q2 2024, down 716.0% year-over-year from 4.36% in Q3 2023, and down 20.11% quarter-over-quarter from 22.36% in Q1 2024.
Oruka Therapeutics (ORKA) Return on Capital Employed (2011 - 2024) Analysis & Trends
Oruka Therapeutics' Return on Capital Employed history runs 14 years deep, the most recent figure standing at 26.85% for Q2 2024.
- In Q2 2024, Return on Capital Employed fell 716.0% year-over-year to 26.85%; the TTM figure through Jun 2024 stood at 26.85% (down 716.0% YoY), while the FY2023 annual figure was 18.32%, up 382.0% from the prior year.
- Return on Capital Employed for Q2 2024 stood at 26.85%, down from 22.36% in the prior quarter.
- The five-year high for Return on Capital Employed was 18.53% in Q3 2023, with the low at 78.51% in Q1 2020.
- The 5-year median for Return on Capital Employed is 24.98% (2021), against an average of 30.86%.
- Peak annual rise in Return on Capital Employed reached 5650 bps in 2021, while the deepest fall reached 1529 bps in 2021.
- Oruka Therapeutics' Return on Capital Employed stood at 20.47% in 2020, then sank by 75 bps to 35.77% in 2021, then jumped by 31 bps to 24.7% in 2022, then grew by 22 bps to 19.26% in 2023, then slumped by 39 bps to 26.85% in 2024.
- Business Quant data shows ORKA's Return on Capital Employed at 26.85% in Q2 2024, 22.36% in Q1 2024, and 19.26% in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Oruka Therapeutics | 6.98 Bn | 5.25 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -26.85% |
| Mar 31, 2024 | -22.36% |
| Dec 31, 2023 | -19.26% |
| Sep 30, 2023 | -18.53% |
| Jun 30, 2023 | -19.69% |
| Mar 31, 2023 | -22.07% |
| Dec 31, 2022 | -24.70% |
| Sep 30, 2022 | -33.03% |
| Jun 30, 2022 | -36.13% |
| Mar 31, 2022 | -36.84% |
| Dec 31, 2021 | -35.77% |
| Sep 30, 2021 | -31.52% |
| Jun 30, 2021 | -25.26% |
| Mar 31, 2021 | -22.01% |
| Dec 31, 2020 | -20.47% |
| Sep 30, 2020 | -19.54% |
| Jun 30, 2020 | -62.96% |
| Mar 31, 2020 | -78.51% |
| Dec 31, 2019 | -69.91% |
| Sep 30, 2019 | -67.23% |